Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 61Stomach Neoplasms 27Rectal Neoplasms 20Colonic Neoplasms 19Small Cell Lung Carcinoma 12Pancreatic Neoplasms 11Neoplasm Metastasis 11Locally Advanced Rectal Cancer 5Colorectal Cancer Metastatic 5Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Biliary Tract Neoplasms 4Recurrence 3Liver Neoplasms 3Glioblastoma 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Solid Tumors 2Sarcoma 2Lung Neoplasms 2Glioma 2Gallbladder Neoplasms 2Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 2Advanced Colorectal Cancer 2mCRC 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Second Line Treatment of Gastric Cancer 1

Interventions

regorafenib 1copper dotatate CU-64 1Irinotecan 1Fluorodeoxyglucose F18 1Etoposide 1Copper 1Clinical Trials, Phase II as Topic 1Cisplatin 164Cu-DOTATATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Gastro-enteropancreatic neuroendocrine tumor × Irinotecan × Clear all
NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown
112 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡